An analysis conducted by Starr and associates showed that patients with high disease burden in the liver did not experience liver failure with PRRT.
Jason Starr, DO
Advertisement
Articles by Jason Starr, DO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer
2
Personalized Treatment Plans for Certain Patients with BRCA-Mutated mCRPC
3
Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer
4
FDA Issues Second CRL for RP1/Nivolumab in Advanced Melanoma
5